REPORT ID 15852

United States Cardiovascular Agents Market Report 2017

Publish Date
30-Nov-17
Pages
112
Format
Electronic (PDF)

In this report, the United States Cardiovascular Agents market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Cardiovascular Agents in these regions, from 2012 to 2022 (forecast).

United States Cardiovascular Agents market competition by top manufacturers/players, with Cardiovascular Agents sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    AstraZeneca plc.
    Pfizer Inc.
    Novartis AG
    Merck & Co., Inc.
    Bristol-Myers Squibb Company
    Bayer AG
    Sanofi
    Boehringer Ingelheim GmbH
    F. Hoffmann-La Roche Ltd
    Abbott Laboratories
    Gilead Sciences, Inc.
    Johnson & Johnson
    Astellas Pharma, Inc.
    Eli Lilly and Company
    Otsuka Holdings Co., Ltd.
    Takeda Pharmaceutical Company Limited.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Antianginal Agents
    Antiarrhythmic Agents
    Inotropic Agents
    Miscellaneous Cardiovascular Agents
    Peripheral Vasodilators
    Renin Inhibitors
    Sclerosing Agents
    Vasodilators
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Retail Pharmacies
    Hospital Pharmacies
    Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Cardiovascular Agents Market Report 2017
1 Cardiovascular Agents Overview
    1.1 Product Overview and Scope of Cardiovascular Agents
    1.2 Classification of Cardiovascular Agents by Product Category
        1.2.1 United States Cardiovascular Agents Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Cardiovascular Agents Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Antianginal Agents
        1.2.4 Antiarrhythmic Agents
        1.2.5 Inotropic Agents
        1.2.6 Miscellaneous Cardiovascular Agents
        1.2.7 Peripheral Vasodilators
        1.2.8 Renin Inhibitors
        1.2.9 Sclerosing Agents
        1.2.10 Vasodilators
    1.3 United States Cardiovascular Agents Market by Application/End Users
        1.3.1 United States Cardiovascular Agents Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 Retail Pharmacies
        1.3.3 Hospital Pharmacies
        1.3.4 Online Pharmacies
    1.4 United States Cardiovascular Agents Market by Region
        1.4.1 United States Cardiovascular Agents Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Cardiovascular Agents Status and Prospect (2012-2022)
        1.4.3 Southwest Cardiovascular Agents Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Cardiovascular Agents Status and Prospect (2012-2022)
        1.4.5 New England Cardiovascular Agents Status and Prospect (2012-2022)
        1.4.6 The South Cardiovascular Agents Status and Prospect (2012-2022)
        1.4.7 The Midwest Cardiovascular Agents Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Cardiovascular Agents (2012-2022)
        1.5.1 United States Cardiovascular Agents Sales and Growth Rate (2012-2022)
        1.5.2 United States Cardiovascular Agents Revenue and Growth Rate (2012-2022)

2 United States Cardiovascular Agents Market Competition by Players/Suppliers
    2.1 United States Cardiovascular Agents Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Cardiovascular Agents Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Cardiovascular Agents Average Price by Players/Suppliers (2012-2017)
    2.4 United States Cardiovascular Agents Market Competitive Situation and Trends
        2.4.1 United States Cardiovascular Agents Market Concentration Rate
        2.4.2 United States Cardiovascular Agents Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Cardiovascular Agents Manufacturing Base Distribution, Sales Area, Product Type

3 United States Cardiovascular Agents Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Cardiovascular Agents Sales and Market Share by Region (2012-2017)
    3.2 United States Cardiovascular Agents Revenue and Market Share by Region (2012-2017)
    3.3 United States Cardiovascular Agents Price by Region (2012-2017)

4 United States Cardiovascular Agents Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Cardiovascular Agents Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Cardiovascular Agents Revenue and Market Share by Type (2012-2017)
    4.3 United States Cardiovascular Agents Price by Type (2012-2017)
    4.4 United States Cardiovascular Agents Sales Growth Rate by Type (2012-2017)

5 United States Cardiovascular Agents Sales (Volume) by Application (2012-2017)
    5.1 United States Cardiovascular Agents Sales and Market Share by Application (2012-2017)
    5.2 United States Cardiovascular Agents Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Cardiovascular Agents Players/Suppliers Profiles and Sales Data
    6.1 AstraZeneca plc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Cardiovascular Agents Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 AstraZeneca plc. Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Pfizer Inc.
        6.2.2 Cardiovascular Agents Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Pfizer Inc. Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novartis AG
        6.3.2 Cardiovascular Agents Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis AG Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Merck & Co., Inc.
        6.4.2 Cardiovascular Agents Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Merck & Co., Inc. Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Bristol-Myers Squibb Company
        6.5.2 Cardiovascular Agents Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Bristol-Myers Squibb Company Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Bayer AG
        6.6.2 Cardiovascular Agents Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Bayer AG Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Sanofi
        6.7.2 Cardiovascular Agents Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Sanofi Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Boehringer Ingelheim GmbH
        6.8.2 Cardiovascular Agents Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Boehringer Ingelheim GmbH Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 F. Hoffmann-La Roche Ltd
        6.9.2 Cardiovascular Agents Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 F. Hoffmann-La Roche Ltd Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Abbott Laboratories
        6.10.2 Cardiovascular Agents Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Abbott Laboratories Cardiovascular Agents Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Gilead Sciences, Inc.
    6.12 Johnson & Johnson
    6.13 Astellas Pharma, Inc.
    6.14 Eli Lilly and Company
    6.15 Otsuka Holdings Co., Ltd.
    6.16 Takeda Pharmaceutical Company Limited.

7 Cardiovascular Agents Manufacturing Cost Analysis
    7.1 Cardiovascular Agents Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Cardiovascular Agents

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Cardiovascular Agents Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Cardiovascular Agents Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Cardiovascular Agents Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Cardiovascular Agents Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Cardiovascular Agents Sales Volume Forecast by Type (2017-2022)
    11.3 United States Cardiovascular Agents Sales Volume Forecast by Application (2017-2022)
    11.4 United States Cardiovascular Agents Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer